170 related articles for article (PubMed ID: 34583727)
41. Current Landscape and Future Prospects of Radiation Sensitizers for Malignant Brain Tumors: A Systematic Review.
Beg U; Snyder BM; Madhani SI; Hamidi N; Padmanaban V; Tuanquin LC; Kruser TJ; Connor J; Mansouri A
World Neurosurg; 2021 Jul; 151():e839-e856. PubMed ID: 33974987
[TBL] [Abstract][Full Text] [Related]
42. Radiation and high-dose metronidazole in supratentorial glioblastomas.
Urtasun R; Band P; Chapman JD; Feldstein ML; Mielke B; Fryer C
N Engl J Med; 1976 Jun; 294(25):1364-7. PubMed ID: 177873
[TBL] [Abstract][Full Text] [Related]
43. Microenvironmental regulation of glioblastoma radioresponse.
Jamal M; Rath BH; Williams ES; Camphausen K; Tofilon PJ
Clin Cancer Res; 2010 Dec; 16(24):6049-59. PubMed ID: 21037023
[TBL] [Abstract][Full Text] [Related]
44. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
Prados MD; Scott CB; Rotman M; Rubin P; Murray K; Sause W; Asbell S; Comis R; Curran W; Nelson J; Davis RL; Levin VA; Lamborn K; Phillips TL
Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):653-9. PubMed ID: 9486616
[TBL] [Abstract][Full Text] [Related]
45. Treating Glioblastoma Multiforme (GBM) with super hyperfractionated radiation therapy: Implication of temporal dose fractionation optimization including cancer stem cell dynamics.
Yu VY; Nguyen D; O'Connor D; Ruan D; Kaprealian T; Chin R; Sheng K
PLoS One; 2021; 16(2):e0245676. PubMed ID: 33524046
[TBL] [Abstract][Full Text] [Related]
46. Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory.
Chadha M; Capala J; Coderre JA; Elowitz EH; Iwai J; Joel DD; Liu HB; Wielopolski L; Chanana AD
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):829-34. PubMed ID: 9531367
[TBL] [Abstract][Full Text] [Related]
47. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
48. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Zhu P; Zhu JJ
Chin Clin Oncol; 2017 Aug; 6(4):41. PubMed ID: 28841803
[TBL] [Abstract][Full Text] [Related]
49. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.
Johannessen TC; Bjerkvig R
Expert Rev Anticancer Ther; 2012 May; 12(5):635-42. PubMed ID: 22594898
[TBL] [Abstract][Full Text] [Related]
50. MiR-26a enhances the radiosensitivity of glioblastoma multiforme cells through targeting of ataxia-telangiectasia mutated.
Guo P; Lan J; Ge J; Nie Q; Guo L; Qiu Y; Mao Q
Exp Cell Res; 2014 Jan; 320(2):200-8. PubMed ID: 24211747
[TBL] [Abstract][Full Text] [Related]
51. New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells.
Würth R; Barbieri F; Florio T
Biomed Res Int; 2014; 2014():126586. PubMed ID: 24527434
[TBL] [Abstract][Full Text] [Related]
52. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma.
Wachsberger PR; Lawrence YR; Liu Y; Rice B; Feo N; Leiby B; Dicker AP
J Cancer Res Clin Oncol; 2014 Apr; 140(4):573-82. PubMed ID: 24500492
[TBL] [Abstract][Full Text] [Related]
53. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
Tung B; Ma D; Wang S; Oyinlade O; Laterra J; Ying M; Lv SQ; Wei S; Xia S
BMC Cancer; 2018 Oct; 18(1):1025. PubMed ID: 30348136
[TBL] [Abstract][Full Text] [Related]
54. Synchrotron-based photon activation therapy effect on cisplatin pre-treated human glioma stem cells.
Ceresa C; Nicolini G; Semperboni S; Requardt H; Le Duc G; Santini C; Pellei M; Bentivegna A; Dalprà L; Cavaletti G; Bravin A
Anticancer Res; 2014 Oct; 34(10):5351-5. PubMed ID: 25275028
[TBL] [Abstract][Full Text] [Related]
55. XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer.
Ferreiro-Neira I; Torres NE; Liesenfeld LF; Chan CH; Penson T; Landesman Y; Senapedis W; Shacham S; Hong TS; Cusack JC
Clin Cancer Res; 2016 Apr; 22(7):1663-73. PubMed ID: 26603256
[TBL] [Abstract][Full Text] [Related]
56. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa').
Stea B; Falsey R; Kislin K; Patel J; Glanzberg H; Carey S; Ambrad AA; Meuillet EJ; Martinez JD
Cancer Lett; 2003 Dec; 202(1):43-51. PubMed ID: 14643025
[TBL] [Abstract][Full Text] [Related]
57. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Alshami J; Guiot MC; Owen S; Kavan P; Gibson N; Solca F; Cseh A; Reardon DA; Muanza T
Oncotarget; 2015 Oct; 6(32):34030-7. PubMed ID: 26423602
[TBL] [Abstract][Full Text] [Related]
58. Novel Strategies for Nanoparticle-Based Radiosensitization in Glioblastoma.
Ruiz-Garcia H; Ramirez-Loera C; Malouff TD; Seneviratne DS; Palmer JD; Trifiletti DM
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575840
[TBL] [Abstract][Full Text] [Related]
59. Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90.
Dungey FA; Caldecott KW; Chalmers AJ
Mol Cancer Ther; 2009 Aug; 8(8):2243-54. PubMed ID: 19671736
[TBL] [Abstract][Full Text] [Related]
60. Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma.
Nieder C; Mehta MP
Med Hypotheses; 2011 Mar; 76(3):410-3. PubMed ID: 21112157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
